435 related articles for article (PubMed ID: 31961624)
1. Bladder preservation in muscle-invasive bladder cancer: a comprehensive review.
Hamad J; McCloskey H; Milowsky MI; Royce T; Smith A
Int Braz J Urol; 2020; 46(2):169-184. PubMed ID: 31961624
[TBL] [Abstract][Full Text] [Related]
2. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
[TBL] [Abstract][Full Text] [Related]
3. Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review.
Koga F; Kihara K
Int J Urol; 2012 May; 19(5):388-401. PubMed ID: 22409269
[TBL] [Abstract][Full Text] [Related]
4. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
Cahn DB; Handorf EA; Ghiraldi EM; Ristau BT; Geynisman DM; Churilla TM; Horwitz EM; Sobczak ML; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG; Smaldone MC
Cancer; 2017 Nov; 123(22):4337-4345. PubMed ID: 28743162
[TBL] [Abstract][Full Text] [Related]
5. Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients.
Kijima T; Tanaka H; Koga F; Masuda H; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
BJU Int; 2019 Aug; 124(2):242-250. PubMed ID: 30811784
[TBL] [Abstract][Full Text] [Related]
6. Selective organ preservation in muscle-invasive bladder cancer: review of the literature.
Khosravi-Shahi P; Cabezón-Gutiérrez L
Surg Oncol; 2012 Mar; 21(1):e17-22. PubMed ID: 22088598
[TBL] [Abstract][Full Text] [Related]
7. Surgical bladder-preserving techniques in the management of muscle-invasive bladder cancer.
Lyons MD; Smith AB
Urol Oncol; 2016 Jun; 34(6):262-70. PubMed ID: 26725219
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of radical cystectomy in potential candidates for bladder preservation therapy.
Pietzak EJ; Sterling ME; Smith ZL; Malkowicz SB; Guzzo TJ
Urology; 2015 Apr; 85(4):869-75. PubMed ID: 25681831
[TBL] [Abstract][Full Text] [Related]
9. Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions.
Jiang DM; Chung P; Kulkarni GS; Sridhar SS
Curr Oncol Rep; 2020 Feb; 22(2):14. PubMed ID: 32008105
[TBL] [Abstract][Full Text] [Related]
10. Bladder-sparing treatment of invasive bladder cancer.
Rivera I; Wajsman Z
Cancer Control; 2000; 7(4):340-6. PubMed ID: 10895128
[TBL] [Abstract][Full Text] [Related]
11. Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Johnson SB; Yu JB
Curr Oncol Rep; 2018 Jun; 20(9):66. PubMed ID: 29959582
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of bladder preservation therapy on survival in patients with muscle-invasive bladder cancer.
Özaydın Ş; Ataş E; Karadurmuş N; Emirzeoğlu L; Arpacı F
Arch Esp Urol; 2020 Jan; 73(1):41-46. PubMed ID: 31950922
[TBL] [Abstract][Full Text] [Related]
13. Bladder sparing surgery in high-grade bladder cancer.
Yakovlev PG; Klyushin DA; Vereshchako RI
Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149
[TBL] [Abstract][Full Text] [Related]
14. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder.
Gakis G; Efstathiou J; Lerner SP; Cookson MS; Keegan KA; Guru KA; Shipley WU; Heidenreich A; Schoenberg MP; Sagaloswky AI; Soloway MS; Stenzl A;
Eur Urol; 2013 Jan; 63(1):45-57. PubMed ID: 22917985
[TBL] [Abstract][Full Text] [Related]
15. Treatment strategies using transurethral surgery, chemotherapy, and radiation therapy with selection that safely allows bladder conservation for invasive bladder cancer.
Kanady KE; Shipley WU; Zietman AL; Kaufman DS; Althausen AF; Heney NM
Semin Surg Oncol; 1997; 13(5):359-64. PubMed ID: 9259092
[TBL] [Abstract][Full Text] [Related]
16. Trimodality therapy in bladder cancer: who, what, and when?
Premo C; Apolo AB; Agarwal PK; Citrin DE
Urol Clin North Am; 2015 May; 42(2):169-80, vii. PubMed ID: 25882559
[TBL] [Abstract][Full Text] [Related]
17. Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers.
El-Taji OM; Alam S; Hussain SA
Curr Treat Options Oncol; 2016 Mar; 17(3):15. PubMed ID: 26942590
[TBL] [Abstract][Full Text] [Related]
18. Challenges in the treatment of bladder cancer.
Kaufman DS
Ann Oncol; 2006 May; 17 Suppl 5():v106-12. PubMed ID: 16807436
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
20. Trimodal therapy for muscle-invasive bladder cancer.
Mathes J; Rausch S; Todenhöfer T; Stenzl A
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1219-1229. PubMed ID: 30324833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
